Proton Pump Inhibitors: Reported Risks
Proton pump inhibitors (PPIs) are among the most prescribed classes of drugs in this day and age.
PPI’s are used for patients with an array of GI conditions, including:
Peptic ulcer disease
Helicobacter pylori infection
Six PPIs are approved by the Food & Drug Administration (FDA): Omeprazole
Concerns continue to surface regarding their use and potential complications:
Below are 10 Reported Concerns with PPI’s:
Due to possible interference with the absorption of calcium salts and inhibition of bone remodeling.
Linked to cardiovascular and non-cardiovascular mortality, arrhythmias, muscle weakness, tetany, or convulsions.
Suppression of acid potentially leading to malabsorption.
Inhibits the cleavage of vitamin B12 from dietary proteins, and reduces absorption.
Community Acquired Pneumonia:
Acid suppression has lead to increased risk.
Higher pH, allowing bacteria, such as, C. Difficile, salmonella, etc. to remain stable and increase risk of infection. .
Linked to acute and chronic kidney disease as well as progression from chronic kidney disease to end-stage renal disease.
Linked in acute cardiac events by inhibiting nitric oxide synthase activity.
Dementia & Alzheimers
Lower levels of protective vitamin B12 or direct inhibition of the enzymatic clearance of β-amyloid.
Thoughts? Questions? Comments?
Write them below. .
Brisebois et al.: Risks of Proton Pump Inhibitors. Laryngoscope Investigative Otolaryngology 3: December 2018.